Speech by the President of the Republic on the ten-year national strategy to combat cancer.

France Emmanuel Macron · President of France

4 February 2021 · Presentation of the ten-year national strategy to combat cancer

Context
Macron addressed researchers, caregivers, and policymakers on 4 February 2021 to launch France's ambitious ten-year national strategy to combat cancer.
Main themes
National cancer strategy, cancer prevention, tobacco control, alcohol reduction, cancer research funding, quality of life for patients, mortality reduction, youth health behaviors, long-term health policy, early detection, treatment innovation
Duration
~18 min
61st percentile
Words
2,193
61st percentile
Sentences
130
75th percentile
Readability
57
82nd percentile
Grade
9.5
15th percentile
Syntax
2.79
21st percentile
Vocabulary
2.13
33rd percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 74%74%
  • Economic 6%6%
  • Institutional 5%5%
  • Ceremonial 5%5%
  • Geopolitical 3%3%
  • Technological 3%3%
  • Environmental 3%3%
  • Not in focus 0%

130 sentences in 40 paragraphs

Ladies and Gentlemen,

The new national cancer control strategy is always an important moment for our Nation, a moment when researchers, caregivers, association leaders, public decision-makers, patients, and former patients come together, as a symbol of our mobilization to combat this disease.

Indeed, we are launching a strategy of great ambition today, which is the result of your collective commitment.

This strategy is ambitious. Ambitious first, by its duration. For the first time, it is a project not for 5 years but for 10 years that has been developed by the National Cancer Institute, whose President, Norbert IFRAH, I salute. Ten years changes everything: it provides visibility for all stakeholders, allows for bold bets, and thus promises more breakthrough innovations and deeper transformations.

This strategy is also ambitious in terms of its funding. 1.7 billion euros mobilized over the next 5 years. That is 20% more than between 2016 and 2021.

This strategy is ambitious also in terms of the objectives pursued.

To reduce the number of 150,000 new avoidable cancers per year to less than 100,000 in a decade.

To decrease the mortality of the 7 deadliest cancers.

To better support the consequences of cancers and treatments on quality of life and employment: because today, two-thirds of patients retain sequelae five years after diagnosis; we aim to bring this population down to less than one-third.

Behind these figures, which are often cold and impersonal, are lives. Mourning that can be avoided. Families that can rebuild. Hope for many patients. That is why, despite the difficulties of the times, despite this pandemic that has delayed too many treatments, especially for cancer patients, I wanted to take action with you. Because improving the lives of the 5 million French families affected by cancer cannot wait.

The Government will present in detail all the measures that will be listed in a decree.

But I want to outline the main priorities here.

1)

First, to do everything possible to minimize the number of cancers by acting over the long term, that of prevention.

Prevention is one of the red threads of the policies we have been pursuing since the beginning of the five-year term: acting at the root, investing upstream to avoid human and financial costs downstream. This is, by the way, one of the weaknesses, it must be said, of the French model. We treat very well, sometimes much better than elsewhere. We often prevent less well. In the face of cancer, this approach is essential. 40% of cancers could be avoided through more virtuous behaviors. Thus, the first way to treat cancer is to ensure that it does not occur.

The various plans that have succeeded one another have allowed us to make progress in many areas: tobacco and alcohol consumption, diet, physical activity, and sports. Our goal today is to consolidate these gains and to change scale.

Tobacco is, and remains, the cause of 70,000 new cases of cancer each year. 70,000. That is almost half of avoidable cancers. Tobacco kills. It destroys lives. We cannot say it enough. I want the generation that will be 20 years old in 2030 to be the first generation without tobacco in recent history. To achieve this, all deterrent levers will be activated: price, we have already made significant progress and we will continue, the extension of smoke-free areas, information campaigns about its toxicity for both people and the planet, better support for those who quit smoking and those who help them. This is a mobilization of society as a whole that we are engaging in. A mobilization that must start, and do even more, from school, drawing inspiration from the greatest successes internationally.

Alcohol is another risk factor, responsible for one-fifth of avoidable cancers. So, of course, alcohol, particularly the alcoholic beverages produced in France that are part of our traditions, belong to our way of life, our sociability. It is not about moving towards zero alcohol but rather about preventing excesses and better helping those who are in some form of dependence to break free. And here too, we must not confuse everything, but we must confront the situation we are currently experiencing with a lot of determination, which remains critical. Just as we have done for food, we will provide consumers with more visible and understandable guidelines for each product. We must do everything to ensure that those most dependent on alcohol reduce their consumption and also to better prevent, inform, and support.

Against these two main causes of avoidable cancers, our actions will particularly target young people so that good practices are adopted as early as possible and have a long-term prescriptive effect, as the behaviors of today's youth will inspire those of future generations. Because what we manage to do in our youth also impacts parents, often.

Finally, fighting cancer means encouraging everyone to adopt a better lifestyle. It is about diet, and France has been a pioneer in deploying the Nutriscore. All the initiatives we are taking to eat better, to promote fresh and local produce, to have affordable and quality agriculture, are fully consistent with this strategy. It is about sports, and this should be taught from school. We must act quickly on this aspect of quality of life. Here too, we have strengthened actions from a very young age, and the strategy proposes several extremely important consolidation axes.

Quality of life also includes the air we breathe. So when we establish "Low Emission Zones" in our cities, it is good for the climate but also good for health. Indeed, environmental policy is simultaneously a public health policy. In 2021, France will have at least 7 new zones of this type, and this is an action I want to strengthen in these metropolitan areas as well as in some of our valleys that remain extraordinarily polluted and affect the health of many of our fellow citizens.

2)

The second axis of our strategy is, in contrast, shorter in time: it is the development of screening, which must be both accessible to all and as early as possible.

Because the earlier cancers are detected, the greater the chances of recovery and the lower the risk of sequelae.

The actions taken over the past twenty years have led to significant advances. In France, 9 million people are screened each year. But we are not there yet. For example, 7 out of 10 people have not been screened for colorectal cancer, whereas 90% of these cancers can be cured if detected at an early stage. Therefore, we must redouble our efforts, both to raise awareness, to overcome hesitations, to mobilize caregivers as well as associations, and to simplify access to tests. I want us to achieve at least 1 million additional screenings per year in the coming years. These screenings are an essential part of the proposed strategy for good reason. As I said, it is a matter of information, mobilizing all stakeholders, and the ability to reach the final audiences and carry out these additional screenings.

We also need to look ahead, inventing the screenings of tomorrow by mobilizing all the contributions of research and technological innovations such as artificial intelligence and big data. Several innovations are underway that allow for better targeting, and thus better prevention thanks to these technologies, sometimes avoiding unnecessary procedures following the initial assessment, and thus improving our screening. Let us set ourselves a priority: that, in a few years, we have deployed campaigns for lung cancer at least as effective as those currently in place for the cancers I just mentioned. Then, we will have cleared a new frontier.

3) The third axis of our strategy, finally: better support for patients. During the illness. And after.

Treatments have already made great progress. But the real revolutions are ahead of us. They are called biotherapy, immunotherapy, fields in which France is at the forefront, areas where we can continue to improve, strengthen our innovations, our funding, and simplify our procedures by accelerating them. They are also called molecular genomics, and here too, we are pioneers. All of this brings the hope of more personalized treatments, less burdensome in terms of sequelae, more humane. That is why we will invest massively in these areas to stay ahead, and sometimes to try to make up for the small delays we may have taken; I am realistic about our situation. 50% of the overall budget of the ten-year strategy is thus dedicated to the research component, both fundamental and clinical. These are investments, teams to encourage and consolidate, the ability to train the best talents and retain them, the ability to develop national strategies on each of the axes I have just mentioned, and I will have the opportunity to do so in the coming weeks in addition to this strategy and this ten-year plan.

It is also about providing visibility on prices when we innovate, and France, it must be said, has not always been good on this subject. And it is about simplifying and accelerating all our procedures. We are still too slow, too sluggish. And, I must say, these delays, not always justified, are obstacles to innovation.

For the most serious cancers, the greatest risk is fundamentally not to take them on. That is why we will work on this acceleration I just mentioned: accelerating the market entry of certain therapies, with simplified procedures.

The issue of cancer sequelae has long been a blind spot and constitutes an important axis of this strategy. Until recently, we wanted to cure at all costs, without always considering the aftermath. And I must say that by listening to you, reading you, and seeing the mobilization of all professionals, I have been impressed by the enrichment of the reflection. And fundamentally, whether it is pediatric oncology or all related specialties, whether it is also forms of cancer that we are now treating better and better, resulting in patients in remission and then cured for years, the question of living long with the consequences, the sequelae of cancer, is a question you have decided to take into account, and I fully support that. We must indeed better take this dimension into account, and this, from the development of therapies. Sequelae are also what we experience when cancer has forced us to leave studies, a job, doors that close. So, in this regard, France has sometimes been a leader, with, for example, the right to be forgotten, and this is a question that many of you have already explored, on which, thanks to you, we have been able to advance and inspire other countries. Today, we must go further. 20% of people who have left their jobs due to cancer have not found it again five years after diagnosis. Together with the private sector, we will change this. So as not to add injustice to injustice.

All these objectives obviously set the bar high. But we can achieve them because we are not alone. If it is a national ambition, the fight against cancer is also a European battle, forcefully affirmed yesterday through the announcements of the Union plan: the creation of a European knowledge center on cancer and a network of care centers, the launch of an initiative on medical imaging for screening and diagnosis, support for States for vaccination against cervical cancer and the papillomavirus, but also for the development of gene therapies.

Ultimately, a watchword has been given: "unite our forces to progress." Together, we can do better, faster. We are experiencing and demonstrating this in the fight against the epidemic. This is what we must do in this fight against cancers.

So, Ladies and Gentlemen, despite the pandemic, France, hand in hand with Europe, will not yield anything of its ambition to combat cancer.

It will not yield anything, in particular, of its action to combat childhood cancer. 1,700 new cases are reported each year, 1,700. Of course, 80% recover. But that is still too few. Above all, we must better support patients to enable them to continue their studies, to engage in activities, to maintain that part of carefreeness that belongs to their age and must be preserved even when fate strikes. Supporting their families as well. In each of these battles that make up your daily life and touch so many lives, you will always have me by your side.

Ladies and Gentlemen,

Let us be proud to be a country where treatment for this terrible illness is free even when the treatments are costly.

Proud to be a country that invests in research, that embraces this humanism that has shaped our history and that holds us together regardless of the tragic times.

So I want to thank you. Thank you all. Because with you I believe in science, I believe in progress. I also believe in the remarkable results that a collective mobilization can achieve when we harness our values and our knowledge. Together we can win this fight. So much has been done over the past years, we can do much more with this decade plan still. That is exactly what I intend to do with you, thanks to you.

Thank you very much.